Target intelligence / Profile preview

General CoA-dependent acyltransferases and ligases

Molecular classification
Enzyme, Transferase, Ligase
01

Overview

General CoA-dependent acyltransferases and ligases represent a broad superfamily of enzymes that utilize Coenzyme A (CoA) as a central cofactor to catalyze the transfer of acyl groups to various substrates or the ligation of carboxylic acids to CoA. This classification encompasses several critical metabolic enzyme families, including diacylglycerol acyltransferases (DGAT), acyl-CoA:cholesterol acyltransferases (ACAT), and histone acetyltransferases (HATs), as well as various acyl-CoA synthetases. These enzymes are essential for the biosynthesis of complex lipids such as triacylglycerols and cholesterol esters, and they play pivotal roles in cellular energy storage, membrane structure, and epigenetic regulation. Due to their fundamental involvement in lipid homeostasis, they are primary therapeutic targets for metabolic disorders like obesity, type 2 diabetes, and atherosclerosis. Furthermore, pharmacological modulation of these enzymes is being explored in oncology and inflammatory diseases to address metabolic reprogramming and aberrant gene expression. Small-molecule inhibitors designed for these targets typically aim to block the binding of acyl-CoA or the acceptor substrate, thereby altering lipid profiles or cellular signaling pathways.

Other names
CoA-dependent acyltransferasesAcyl-CoA ligasesAcyl-CoA dependent acyltransferasesAcyltransferases and ligasesGNAT superfamily enzymes
02

Mechanism of action

Inhibition of acyl group transfer from acyl-CoA to substrates or inhibition of carboxylic acid ligation to Coenzyme A to modulate lipid flux and protein modification.

03

Biological functions

Lipid metabolismFatty acid activationProtein acetylationTriacylglycerol synthesisCholesterol esterificationXenobiotic metabolism
04

Disease associations

Metabolic syndromeObesityDyslipidemiaAtherosclerosisCancerNon-alcoholic fatty liver disease (NAFLD)
05

Safety considerations

HepatotoxicityGastrointestinal distress (e.g., diarrhea with DGAT inhibitors)Adrenal cortical depletion (observed with some ACAT inhibitors)Potential for systemic metabolic disruption
06

Interacting drugs

Avasimibe

5 more in the full profile.

07

Biomarkers

Serum triglyceridesLDL cholesterolHDL cholesterolLiver fat contentHistone acetylation levels

Beyond the preview

Go deeper on General CoA-dependent acyltransferases and ligases.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on General CoA-dependent acyltransferases and ligases.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call